U.S. House Passes FDA Modernization Act 3.0, Replacing Preclinical Animal Testing Regulations for Companies Like Vanda (VNDA)
Legislative Breakthrough for Harmonizing Preclinical Regulations
The U.S. House of Representatives passed the 'FDA Modernization Act 3.0 (H.R. 2821)' with a majority vote, aiming to reduce reliance on animal testing and accelerate the adoption of alternative testing methods in the drug development process. This bill mandates that the Food and Drug Administration (FDA) immediately update its sub-regulations, which still define animal testing as the standard, to align with federal law. These sub-regulations had not been updated despite the passage of the 'FDA Modernization Act 2.0' in 2022, which eliminated mandatory animal testing clauses. Representative Buddy Carter, the bill's sponsor, stated that this passage marks a turning point in transforming the human drug evaluation system into a more efficient and humane one. This strong regulatory reform initiative by the legislature will serve as a crucial catalyst for integrating advanced non-animal testing models into the preclinical research phase.
Institutionalization of New Methodologies and Industry Perspectives
The FDA has outlined a plan to restrict animal testing in preclinical toxicity assessments to exceptional cases within the next 3-5 years, as detailed in its '2025 Animal Testing Phase-Out Roadmap.' The regulatory agency also released a draft guideline in March 2026, stating that it will review data from 'New Approach Methodologies (NAMs)' such as organoids and organs-on-chips without prior approval. However, some in the pharmaceutical industry, including Vanda Pharmaceuticals (VNDA), have expressed concerns that the regulatory agency's guidelines are too vague and that there is a lack of concrete success stories for specific alternative testing methods. These concerns highlight the practical barriers that innovative technology development companies will face in the actual approval process, and that thorough validation data accumulation is essential for complete institutionalization.
Massive Federal Government Investment and Ecosystem Development
In line with the regulatory changes, the National Institutes of Health (NIH) has decided to invest a substantial amount of funding, exceeding USD 150 million, in the 'Complement-ARIE' program to support non-animal alternative preclinical research. This follows the NIH's previous investment of USD 87 million for organoid development and the establishment of a dedicated department, demonstrating the public sector's commitment to building the foundation of the technology ecosystem. In March 2026, seven new advanced technology development centers were designated, aiming to accelerate technology standardization through data sharing and overcoming biological complexity.
High Growth Prospects for the Global Alternative Market and Market Leadership
With regulatory easing and government investment working in tandem, the global organoid and organ-on-chip market is expected to experience rapid growth. According to industry reports, the global organoid market is projected to reach up to USD 2.7 billion in 2026 and grow at an annual rate of approximately 19%, reaching USD 7.07 billion in 2034. The organ-on-chip market is also expected to grow from USD 150 million in 2026 to a multi-billion dollar market in the mid-2030s, with an annual growth rate of up to 35%. North America is expected to maintain its leading position in this trend, with emerging biotech companies in the Asia-Pacific region rapidly catching up to close the technology gap.
The passage of the FDA Modernization Act 3.0 in the House of Representatives provides the legal force to formally replace the existing paradigm of using animal models to evaluate drug toxicity and efficacy in the preclinical phase with new approach methodologies (NAMs) such as organoids and organs-on-chips. In the short term, the NIH's USD 150 million 'Complement-ARIE' funding program will provide liquidity and accelerate the commercialization of related technologies. In the medium to long term, it will lead to increased success rates in preclinical trials and shorten the time to market for new drug candidates. However, as pointed out by companies such as Vanda Pharmaceuticals (VNDA), the absence of standardized validation guidelines may act as a barrier to early market entry. Nevertheless, with the global organoid market projected to grow to USD 7.07 billion by 2034 from its current size of up to USD 2.7 billion in 2026, the competition among biotech companies to secure a leading position in the preclinical platform will intensify. From an investor's perspective, platform companies that demonstrate exclusive patents and reproducible data in the organ-on-chip ecosystem, which is expected to grow at a very high rate of up to 35% annually, will be the key targets for long-term value creation.